Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PPARD | Q03181 | 14/20 | 0.54 |
| ▸ | PPARA | Q07869 | 13/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.53 |
| ▸ | PPARG | P37231 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3747857 | 0.82 | NPC1 (0.53) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL3739502 | 0.82 | NPC1 (0.53) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL3745248 | 0.82 | NPC1 (0.53) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL21013647 | 0.81 | NPC1 (0.51) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL27650489 | 0.80 | NPC1 (0.56) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL3371882 | 0.78 | NPC1 (0.53) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL4856486 | 0.78 | NPC1 (0.53) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL4856478 | 0.78 | NPC1 (0.53) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL3743300 | 0.78 | NPC1 (0.51) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL6221868 | 0.77 | NPC1 (0.52) | NPC1ALDH1A1GAAPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196107-B2 | Thia-and oxazoles and their use as ppars activators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1343772-B1 | THIA- AND OXAZOLES AND THEIR USE AS PPARS ACTIVATORS | GLAXO GROUP LTD (GB) | 2006-05-31 | — | — | EP | disclosed |
| US-20040102493-A1 | Thia-and oxazoles and their use as ppars activators | SMITHKLINE BEECHAM CORPORATION | 2004-05-27 | — | — | US | disclosed |
| EP-1343772-A1 | THIA- AND OXAZOLES AND THEIR USE AS PPARS ACTIVATORS | GLAXO GROUP LIMITED (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002050048-A1 | THIA- AND OXAZOLES AND THEIR USE AS PPARS ACTIVATORS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102493-A1 | Thia-and oxazoles and their use as ppars activators | PPARA, PPARG, NCOA1 | NPC1 779/4885ALDH1A1 2302/4885GAA 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.